サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1076234

移植片対宿主病 (GvHD) 治療薬の世界市場：疫学・パイプライン分析・市場予測 (2022-2027年)

Graft Versus Host Disease (GvHD) Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027
出版日: | 発行: Arizton Advisory & Intelligence | ページ情報: 英文 190 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.46円
移植片対宿主病 (GvHD) 治療薬の世界市場：疫学・パイプライン分析・市場予測 (2022-2027年)
出版日: 2022年05月17日
発行: Arizton Advisory & Intelligence
ページ情報: 英文 190 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

移植片対宿主病 (GvHD) 治療薬の市場規模は、予測期間中7.44%のCAGRで成長すると予測されています。

副腎皮質ステロイドは、フロントラインで広く推奨されることから、28.97%を超える大きなシェアを示しています。また、急性GvHD (aGvHD) は、造血幹細胞移植患者の30～50％が急性GvHDを発症することから、34.73％の重要なシェアを示しています。

当レポートでは、世界の移植片対宿主病 (GvHD) 治療薬の市場を調査し、GvHDの概要、主要8カ国におけるHSCTおよび同種HSCTの件数の推移・予測、主要8カ国におけるaGvHDおよびcGvHDの発症数の推移・予測、主要8カ国市場におけるGvHD収益の推移・予測、上市済み薬およびパイプライン薬の分析、臨床試験の動向、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 GvHDの概要

第2章 GvHDの疫学・概要

  • 主要8カ国市場におけるHSCTおよび同種HSCTの推移・予測
  • 主要8カ国市場におけるHSCTおよび同種HSCTの比較分析
  • 主要8カ国市場におけるaGvHDおよびcGvHDの発症数の推移・予測
  • 主要8カ国市場におけるaGvHDおよびcGvHDの発症数の比較分析
  • 米国：HSCTおよび同種HSCTの推移・予測
  • 米国：HSCTおよび同種HSCTの比較分析
  • 米国：aGvHDおよびcGvHDの発症数の推移・予測
  • 米国：aGvHDおよびcGvHDの発症数の比較分析
  • 中国：HSCTおよび同種HSCTの推移・予測
  • 中国：HSCTおよび同種HSCTの比較分析
  • 中国：aGvHDおよびcGvHDの発症数の推移・予測
  • 中国：aGvHDおよびcGvHDの発症数の比較分析
  • ドイツ：HSCTおよび同種HSCTの推移・予測
  • ドイツ：HSCTおよび同種HSCTの比較分析
  • ドイツ：aGvHDおよびcGvHDの発症数の推移・予測
  • ドイツ：aGvHDおよびcGvHDの発症数の比較分析
  • 日本：HSCTおよび同種HSCTの推移・予測
  • 日本：HSCTおよび同種HSCTの比較分析
  • 日本：aGvHDおよびcGvHDの発症数の推移・予測
  • 日本：aGvHDおよびcGvHDの発症数の比較分析
  • フランス：HSCTおよび同種HSCTの推移・予測
  • フランス：HSCTおよび同種HSCTの比較分析
  • フランス：aGvHDおよびcGvHDの発症数の推移・予測
  • フランス：aGvHDおよびcGvHDの発症数の比較分析
  • イタリア：HSCTおよび同種HSCTの推移・予測
  • イタリア：HSCTおよび同種HSCTの比較分析
  • イタリア：aGvHDおよびcGvHDの発症数の推移・予測
  • イタリア：aGvHDおよびcGvHDの発症数の比較分析
  • 英国：HSCTおよび同種HSCTの推移・予測
  • 英国：HSCTおよび同種HSCTの比較分析
  • 英国：aGvHDおよびcGvHDの発症数の推移・予測
  • 英国：aGvHDおよびcGvHDの発症数の比較分析
  • スペイン：HSCTおよび同種HSCTの推移・予測
  • スペイン：HSCTおよび同種HSCTの比較分析
  • スペイン：aGvHDおよびcGvHDの発症数の推移・予測
  • スペイン：aGvHDおよびcGvHDの発症数の比較分析

第3章 GvHDの市場規模・概要

  • 主要8カ国市場におけるGvHD収益の推移・予測
  • 主要8カ国市場におけるGvHD収益の推移・予測：スナップショット
  • 主要8カ国市場におけるGvHDの主要承認済み薬・適応外薬
  • 主要8カ国市場における収益の推移・予測：治療タイプ・性別・医薬品クラス別
  • 米国：GvHD収益の推移・予測
  • 米国：GvHD収益の推移・予測：スナップショット
  • 米国：収益の推移・予測：治療タイプ・性別・医薬品クラス別
  • 中国：GvHD収益の推移・予測
  • 中国：GvHD収益の推移・予測：スナップショット
  • 中国：収益の推移・予測：治療タイプ・性別・医薬品クラス別
  • ドイツ：GvHD収益の推移・予測
  • ドイツ：GvHD収益の推移・予測：スナップショット
  • ドイツ：収益の推移・予測：治療タイプ・性別・医薬品クラス別
  • 日本：GvHD収益の推移・予測
  • 日本：GvHD収益の推移・予測：スナップショット
  • 日本：収益の推移・予測：治療タイプ・性別・医薬品クラス別
  • フランス：GvHD収益の推移・予測
  • フランス：GvHD収益の推移・予測：スナップショット
  • フランス：収益の推移・予測：治療タイプ・性別・医薬品クラス別
  • イタリア：GvHD収益の推移・予測
  • イタリア：GvHD収益の推移・予測：スナップショット
  • イタリア：収益の推移・予測：治療タイプ・性別・医薬品クラス別
  • 英国：GvHD収益の推移・予測
  • 英国：GvHD収益の推移・予測：スナップショット
  • 英国：収益の推移・予測：治療タイプ・性別・医薬品クラス別
  • スペイン：GvHD収益の推移・予測
  • スペイン：GvHD収益の推移・予測：スナップショット
  • スペイン：収益の推移・予測：治療タイプ・性別・医薬品クラス別

第4章 GvHD上市済み薬の概要

  • GvHD市販薬：概要
  • GvHD市販薬：まとめ

第5章 GvHDパイプライン薬の概要

  • GvHDパイプライン薬：概要
  • GvHDパイプライン薬：スナップショット
  • GvHDパイプライン薬の概要・スナップショット：疾患タイプ別
  • GvHDパイプライン薬の概要・スナップショット：開発段階別
  • GvHDパイプライン薬の概要・スナップショット：投与経路別
  • GvHDパイプライン薬の概要・スナップショット：作用機序別
  • GvHDパイプライン薬の概要・スナップショット：分子タイプ別
  • GvHDパイプライン薬の概要・スナップショット：地域別

第6章GvHD：臨床試験の概要

  • GvHD臨床試験の概要：スナップショット
  • GvHD臨床試験の概要：採用状況別
  • GvHD臨床試験の概要：製品タイプ別
  • GvHD臨床試験の概要：投与経路別
  • GvHD臨床試験の概要：分子タイプ別
  • GvHD臨床試験の概要：地域別

第7章 GvHD：市場力学

  • 市場促進要因
  • 市場抑制要因
  • 市場動向

第8章 GvHD：競合情勢

  • GvHDの競合情勢：上市済み薬
  • アンメットニーズ・戦略的推奨事項
  • 適応外および後期医薬品の競合評価
  • 主要企業のプロファイル
  • GvHD治療薬市場の競合シナリオ
  • その他の有力企業プロファイル
  • 主要企業の概要
  • GvHDの競合情勢：パイプライン薬
  • 主要な新興企業のプロファイル
  • 主要な新興企業の概要
  • その他の有力企業のプロファイル

第9章 GvHD：その他

  • 暫定的な医薬品承認タイムライン
  • 主な規制指定
  • 主要なマイルストーン
  • 契約・コラボレーション
  • 休止・製造中止の製品

第10章 付録

図表

LIST OF EXHIBITS

  • Exhibit 1 HISTORIC & PROJECTED VOLUME OF HSCT IN 8 MAJOR MARKETS
  • Exhibit 2 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN 8 MAJOR MARKETS
  • Exhibit 3 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN 8 MAJOR MARKETS (2018-2020)
  • Exhibit 4 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN 8 MAJOR MARKETS (2021 - 2027)
  • Exhibit 5 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN 8 MAJOR MARKETS

Exhibit 6 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN 8 MAJOR MARKETS

  • Exhibit 7 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN 8 MAJOR MARKETS (2018-2020)
  • Exhibit 8 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN 8 MAJOR MARKETS (2021-2027)
  • Exhibit 9 HISTORIC & PROJECTED VOLUME OF HSCT IN UNITED STATES
  • Exhibit 10 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN UNITED STATES
  • Exhibit 11 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED STATES (2018-2020)

Exhibit 12 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED STATES (2021-2027)

  • Exhibit 13 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN UNITED STATES
  • Exhibit 14 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN UNITED STATES
  • Exhibit 15 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED STATES (2018-2020)
  • Exhibit 16 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED STATES (2021-2027)
  • Exhibit 17 HISTORIC & PROJECTED VOLUME OF HSCT IN CHINA

Exhibit 18 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN CHINA

  • Exhibit 19 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN CHINA (2018-2020)
  • Exhibit 20 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN CHINA (2021-2027)
  • Exhibit 21 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN CHINA

Exhibit 22 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN CHINA

  • Exhibit 23 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN CHINA (2018-2020)
  • Exhibit 24 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN CHINA (2021-2027)
  • Exhibit 25 HISTORIC & PROJECTED VOLUME OF HSCT IN GERMANY

Exhibit 26 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN GERMANY

  • Exhibit 27 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN GERMANY (2018-2020)
  • Exhibit 28 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN GERMANY (2021-2027)
  • Exhibit 29 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN GERMANY

Exhibit 30 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN GERMANY

  • Exhibit 31 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN GERMANY (2018-2020)
  • Exhibit 32 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN GERMANY (2021-2027)
  • Exhibit 33 HISTORIC & PROJECTED VOLUME OF HSCT IN JAPAN
  • Exhibit 34 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN JAPAN
  • Exhibit 35 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN JAPAN (2018-2020)
  • Exhibit 36 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN JAPAN (2021-2027)
  • Exhibit 37 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN JAPAN

Exhibit 38 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN JAPAN

  • Exhibit 39 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN JAPAN (2018-2020)
  • Exhibit 40 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN JAPAN (2021-2027)
  • Exhibit 41 HISTORIC & PROJECTED VOLUME OF HSCT IN FRANCE
  • Exhibit 42 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN FRANCE
  • Exhibit 43 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN FRANCE (2018-2020)

Exhibit 44 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN FRANCE (2021-2027)

  • Exhibit 45 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN FRANCE

Exhibit 46 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN FRANCE

  • Exhibit 47 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN FRANCE (2018-2020)
  • Exhibit 48 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN FRANCE (2021-2027)
  • Exhibit 49 HISTORIC & PROJECTED VOLUME OF HSCT IN ITALY

Exhibit 50 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN ITALY

  • Exhibit 51 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN ITALY (2018-2020)
  • Exhibit 52 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN ITALY (2021-2027)
  • Exhibit 53 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN ITALY

Exhibit 54 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN ITALY

  • Exhibit 55 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN ITALY (2018-2020)
  • Exhibit 56 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN ITALY (2021-2027)
  • Exhibit 57 HISTORIC & PROJECTED VOLUME OF HSCT IN UNITED KINGDOM

Exhibit 58 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN UNITED KINGDOM

  • Exhibit 59 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED KINGDOM (2018-2020)
  • Exhibit 60 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED KINGDOM (2021-2027)
  • Exhibit 61 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN UNITED KINGDOM

Exhibit 62 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN UNITED KINGDOM

  • Exhibit 63 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED KINGDOM (2018-2020)
  • Exhibit 64 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED KINGDOM (2021-2027)
  • Exhibit 65 HISTORIC & PROJECTED VOLUME OF HSCT IN SPAIN

Exhibit 66 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN SPAIN

  • Exhibit 67 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN SPAIN (2018-2020)
  • Exhibit 68 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN SPAIN (2021-2027)
  • Exhibit 69 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN SPAIN

Exhibit 70 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN SPAIN

  • Exhibit 71 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN SPAIN (2018-2020)
  • Exhibit 72 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN SPAIN (2021-2027)
  • Exhibit 73 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN 8 MAJOR MARKETS
  • Exhibit 74 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN 8 MAJOR MARKETS
  • Exhibit 75 MAJOR APPROVED & OFF-LABEL DRUGS IN GVHD TREATMENT MARKET
  • Exhibit 76 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN 8 MAJOR MARKETS
  • Exhibit 77 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN 8 MAJOR MARKETS
  • Exhibit 78 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN 8 MAJOR MARKETS
  • Exhibit 79 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN UNITED STATES
  • Exhibit 80 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN UNITED STATES
  • Exhibit 81 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN UNITED STATES
  • Exhibit 82 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN UNITED STATES
  • Exhibit 83 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN UNITED STATES
  • Exhibit 84 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN CHINA
  • Exhibit 85 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN CHINA
  • Exhibit 86 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN CHINA
  • Exhibit 87 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN CHINA
  • Exhibit 88 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN CHINA
  • Exhibit 89 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN GERMANY
  • Exhibit 90 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN GERMANY
  • Exhibit 91 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN GERMANY
  • Exhibit 92 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN GERMANY
  • Exhibit 93 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN GERMANY
  • Exhibit 94 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN JAPAN
  • Exhibit 95 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN JAPAN
  • Exhibit 96 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN JAPAN
  • Exhibit 97 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN JAPAN
  • Exhibit 98 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN JAPAN
  • Exhibit 99 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN FRANCE
  • Exhibit 100 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN FRANCE
  • Exhibit 101 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN FRANCE
  • Exhibit 102 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN FRANCE
  • Exhibit 103 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN FRANCE
  • Exhibit 104 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN ITALY
  • Exhibit 105 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN ITALY
  • Exhibit 106 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN ITALY
  • Exhibit 107 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN ITALY
  • Exhibit 108 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN ITALY
  • Exhibit 109 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN UNITED KINGDOM
  • Exhibit 110 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN UNITED KINGDOM
  • Exhibit 111 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN UNITED KINGDOM
  • Exhibit 112 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN UNITED KINGDOM
  • Exhibit 113 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN UNITED KINGDOM
  • Exhibit 114 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN SPAIN
  • Exhibit 115 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN SPAIN
  • Exhibit 116 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN SPAIN
  • Exhibit 117 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN SPAIN
  • Exhibit 118 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN SPAIN
  • Exhibit 119 MARKETED DRUGS OVERVIEW IN GVHD TREATMENT MARKET
  • Exhibit 120 GVHD PIPELINE DRUGS OVERVIEW SNAPSHOT
  • Exhibit 121 GVHD PIPELINE DRUGS LANDSCAPE SNAPSHOT
  • Exhibit 122 GVHD PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
  • Exhibit 123 GVHD PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
  • Exhibit 124 GVHD PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
  • Exhibit 125 GVHD PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
  • Exhibit 126 GVHD PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
  • Exhibit 127 GVHD PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
  • Exhibit 128 KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUHS IN GVHD
  • Exhibit 129 KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN GVHD
  • Exhibit 130 INACTIVE/DISCONTINUED PIPELINE DRUGS IN GVHD
  • Exhibit 131 COMPETITIVE ASSESSMENT OF GVHD PROPHYLAXIS OFF-LABEL & LATE-STAGE PIPELINE DRUGS
  • Exhibit 132 COMPETITIVE ASSESSMENT OF ACUTE GVHD OFF-LABEL & LATE-STAGE PIPELINE DRUGS
  • Exhibit 133 COMPETITIVE ASSESSMENT OF CHRONIC GVHD OFF-LABEL & LATE-STAGE PIPELINE DRUGS
  • Exhibit 134 GVHD CLINICAL TRIALS OVERVIEW SNAPSHOT

LIST OF TABLES

Table 1 KEY MARKET DRIVERS IN GVHD TREATMENT MARKET

Table 2 KEY MARKET CONSTRAINTS IN GVHD TREATMENT MARKET

Table 3 KEY MARKET TRENDS IN GVHD TREATMENT MARKET

Table 4 COMPETITIVE LANDSCAPE OF MARKETED DRUGS IN GVHD TREATMENT MARKET

Table 5 COMPETITIVE SCENARIO OF GVHD TREATMENT MARKET

Table 6 COMPETITIVE LANDSCAPE OF PIPELINE DRUGS IN GVHD TREATMENT MARKET

目次
Product Code: Sample_Graft Versus Host Disease (GvHD) Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027_Arizton.pdf

The report considers the present scenario of the graft versus host disease market and its market dynamics for the period 2022-2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent companies operating in the market.

The graft versus host disease market to grow at a CAGR of 7.44% during 2021-2027.

SEGMENT ANALYSIS

  • Corticosteroids accounted for the significant share of more than 28.97% in the global GvHD treatment market due to its wide recommendation in front line setting.
  • The acute GVHD (aGVHD) accounted for a significant share of 34.73% in the global graft versus host disease (GVHD) treatment market due to 30% to 50% of hematopoietic stem cell transplant recipients develop acute GVHD.
  • Males are accounted for the significant share of 59.64% in the global GvHD treatment market due to rise in number of hematopoietic stem cell transplantations.

Market Segmentation by Drug Class

  • Corticosteroids
  • Kinase Inhibitors
  • Calcineurin Inhibitors
  • TNF-Alpha Inhibitors
  • Other Class of Drugs

Market Segmentation by Treatment Type

  • GVHD Prophylaxis
  • Chronic GVHD
  • Acute GVHD

Market Segmentation by Gender Type

  • Males
  • Females

GEOGRAPHIC ANALYSIS

  • The United States dominated the graft versus host disease (GVHD) treatment market by geography. However, China is expected to grow faster with a high CAGR in the market. The rise in incidence and prevalence of GVHD patients, presence of key players, and rise in access to health care due to well-established healthcare infrastructure and extensive reach of novel therapeutics are largely driving the United States market.

Market Segmentation by Geography

  • North America
    • US
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
  • APAC
    • China
    • Japan

VENDOR ANALYSIS

  • With more than 134+ molecules in various stages of development, it is expected that new vendors are likely to enter into the market with novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating GVHD.

Key Players

  • Incyte
  • Pharmacyclics
  • Bristol-Myers Squibb
  • JCR Pharmaceuticals Co., Ltd.
  • Takeda Pharmaceutical Co Ltd (Takeda)
  • MaaT Pharma
  • XeniKos
  • Medac GmbH
  • Mesoblast
  • Kadmon
  • Jazz Pharmaceuticals
  • Gsk
  • Novartis
  • Syndax Pharmaceuticals Inc

Other Prominent Vendors

  • Neovii
  • ElsaLys Biotech
  • Mallinckrodt
  • Regimmune
  • Roche
  • Altrubio
  • CTTQ
  • Equillium
  • Janssen (johnson & johnson)
  • ASC Therapeutics
  • MSD
  • Genentech
  • Sun Pharma
  • Mink Therapeutics
  • Pluristem

The Report Covers The following details:

  • Detailed overview of GVHD, including disease definition, classification, diagnosis, and treatment pattern
  • Overview of the global graft versus host disease treatment market trends in the eight major markets (8MM)
  • Historical, current, and projected patient pool of GVHD in the eight major markets (8MM) for the 2018 - 2027 period
  • Disease, Gender, and Drug Class segmentations of the GVHD in the eight major markets (8MM)
  • Historical, current, and projected market size & forecast of GVHD in eight major markets (8MM) for the 2018 - 2027 period
  • In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
  • Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape
  • Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
  • Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
  • Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for GVHD across the complete product development cycle, including all clinical and non-clinical stages
  • Detailed overview of clinical trial activities and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and Geography type for GVHD across all clinical stages
  • Coverage of dormant and discontinued pipeline projects along with the reasons across GVHD
  • Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the GVHD space

TABLE OF CONTENTS

CHAPTER - 1 GVHD OVERVIEW

  • Graft Versus Host Disease - An Overview

CHAPTER - 2 GVHD EPIDEMIOLOGY & OVERVIEW

  • 8MM Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • 8MM Comparative Analysis of HSCT & Allogeneic - HSCT
  • 8MM Historic & Projected Volume of incidence of aGVHD & cGVHD
  • 8MM Comparative Analysis of incidence of aGVHD & cGVHD
  • US Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • US Comparative Analysis of HSCT & Allogeneic - HSCT
  • US Historic & Projected Volume of incidence of aGVHD & cGVHD
  • US Comparative Analysis of incidence of aGVHD & cGVHD
  • China Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • China Comparative Analysis of HSCT & Allogeneic - HSCT
  • China Historic & Projected Volume of incidence of aGVHD & cGVHD
  • China Comparative Analysis of incidence of aGVHD & cGVHD
  • Germany Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • Germany Comparative Analysis of HSCT & Allogeneic - HSCT
  • Germany Historic & Projected Volume of incidence of aGVHD & cGVHD
  • Germany Comparative Analysis of incidence of aGVHD & cGVHD
  • Japan Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • Japan Comparative Analysis of HSCT & Allogeneic - HSCT
  • Japan Historic & Projected Volume of incidence of aGVHD & cGVHD
  • Japan Comparative Analysis of incidence of aGVHD & cGVHD
  • France Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • France Comparative Analysis of HSCT & Allogeneic - HSCT
  • France Historic & Projected Volume of incidence of aGVHD & cGVHD
  • France Comparative Analysis of incidence of aGVHD & cGVHD
  • Italy Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • Italy Comparative Analysis of HSCT & Allogeneic - HSCT
  • Italy Historic & Projected Volume of incidence of aGVHD & cGVHD
  • Italy Comparative Analysis of incidence of aGVHD & cGVHD
  • UK Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • UK Comparative Analysis of HSCT & Allogeneic - HSCT
  • UK Historic & Projected Volume of incidence of aGVHD & cGVHD
  • UK Comparative Analysis of incidence of aGVHD & cGVHD
  • Spain Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • Spain Comparative Analysis of HSCT & Allogeneic - HSCT
  • Spain Historic & Projected Volume of incidence of aGVHD & cGVHD
  • Spain Comparative Analysis of incidence of aGVHD & cGVHD

CHAPTER - 3 GVHD MARKET SIZE & OVERVIEW

  • 8MM Historic & Projected Revenue of GVHD
  • 8MM Historic & Projected Revenue of GVHD Snapshot
  • 8MM Major Approved & Off-label Drugs in GVHD
  • 8MM Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • US Historic & Projected Revenue of GVHD
  • US Historic & Projected Revenue of GVHD Snapshot
  • US Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • China Historic & Projected Revenue of GVHD
  • China Historic & Projected Revenue of GVHD Snapshot
  • China Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • Germany Historic & Projected Revenue of GVHD
  • Germany Historic & Projected Revenue of GVHD Snapshot
  • Germany Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • Japan Historic & Projected Revenue of GVHD
  • Japan Historic & Projected Revenue of GVHD Snapshot
  • Japan Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • France Historic & Projected Revenue of GVHD
  • France Historic & Projected Revenue of GVHD Snapshot
  • France Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • Italy Historic & Projected Revenue of GVHD
  • Italy Historic & Projected Revenue of GVHD Snapshot
  • Italy Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • UK Historic & Projected Revenue of GVHD
  • UK Historic & Projected Revenue of GVHD Snapshot
  • UK Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • Spain Historic & Projected Revenue of GVHD
  • Spain Historic & Projected Revenue of GVHD Snapshot
  • Spain Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class

CHAPTER - 4 GVHD MARKETED DRUGS OVERVIEW

  • GVHD Marketed Drugs - An Overview
  • GVHD Marketed Drugs - Summary

CHAPTER - 5 GVHD PIPELINE DRUGS OVERVIEW

  • GVHD Pipeline Drugs - An Overview
  • GVHD Pipeline Drugs - Snapshot
  • GVHD Pipeline Drugs Overview & Snapshot - By Disease type
  • GVHD Pipeline Drugs Overview & Snapshot - By Development Phase
  • GVHD Pipeline Drugs Overview & Snapshot - By Route of Administration
  • GVHD Pipeline Drugs Overview & Snapshot - By Mechanism of Action
  • GVHD Pipeline Drugs Overview & Snapshot - By Molecule type
  • GVHD Pipeline Drugs Overview & Snapshot - By Geography type

CHAPTER - 6 GVHD CLINICAL TRIALS OVERVIEW

  • GVHD Clinical Trials Overview Snapshot
  • GVHD Clinical Trials Overview - By Recruitment Status
  • GVHD Clinical Trials Overview - By Product type
  • GVHD Clinical Trials Overview - By Route of Administration
  • GVHD Clinical Trials Overview - By Molecule type
  • GVHD Clinical Trials Overview - By Geography type

CHAPTER - 7 GVHD MARKET DYNAMICS

  • GVHD Treatment Market Drivers
  • GVHD Treatment Market Constraints
  • GVHD Treatment Market Trends

CHAPTER - 8 GVHD COMPETITIVE LANDSCAPE

  • GVHD Competitive Landscape - Marketed Drugs
  • Unmet Needs & Strategic Recommendations
  • Competitive Assessment of Off-label & Late-stage Drugs
  • Key Company Profiles
  • Competitive Scenario of GVHD Treatment Market
  • Other Prominent Company Profiles
  • Key Company Overviews
  • GVHD Competitive Landscape - Pipeline Drugs
  • Key Emerging Company Profiles
  • Key Emerging Company Overviews
  • Other Prominent Company Profiles

CHAPTER - 9 GVHD MISCELLANEOUS

  • Key Tentative Drug Approvals Timeline
  • Key Regulatory Designations
  • Key Milestones
  • Deals & Collaborations
  • Inactive/Discontinued/Dormant Products

CHAPTER - 10 APPENDIX

  • About Arizton
  • Research Methodology
  • List of Abbreviations